Pharma major Lupin has announced the creation of a wholly owned subsidiary, LupinLife Consumer Healthcare, a strategic move to sharpen its focus on the fast-growing self-care and over-the-counter (OTC) wellness segment. The carve-out is effective from July 1, 2025.The new entity will house Lupin’s consumer healthcare portfolio, which includes OTC brands such as Softovac, Beplex Forte, Corcium, and Aptivate. The company said the move is aimed at enabling targeted investments, accelerating market expansion, and driving faster growth in the consumer health space.
Anil V. Kaushal has been appointed Chief Executive Officer of LupinLife Consumer Healthcare. The company said the dedicated unit will operate with greater agility and a sharper focus on innovation and consumer access.
The shares of the pharma company ended 1.6% in the green on BSE in the session on Tuesday (July 1).Last week, Lupin announced the launch of Prucalopride tablets in the United States after receiving final approval from the US Food and Drug Administration (USFDA).
Anil V. Kaushal has been appointed Chief Executive Officer of LupinLife Consumer Healthcare. The company said the dedicated unit will operate with greater agility and a sharper focus on innovation and consumer access.
The shares of the pharma company ended 1.6% in the green on BSE in the session on Tuesday (July 1).Last week, Lupin announced the launch of Prucalopride tablets in the United States after receiving final approval from the US Food and Drug Administration (USFDA).
The tablets, used in the treatment of chronic idiopathic constipation (CIC) in adults, are available in 1 mg and 2 mg strengths and are bioequivalent to Motegrity tablets of Takeda Pharmaceuticals U.S.A., Inc.
Also Read: LTIMindtree rolls out GCC-as-a-Service to help firms scale global capability centres
